TRIM66 and sarcoma: A higher expression of TRIM66 is significantly associated with worse survival for KIRC patients and better survival for Sarcoma (SARC), Head and Neck Squamous Cell Carcinoma (HNSC), and Pancreatic Adenocarcinoma (PAAD) patients (Figure 1D).